Quality Improvement Grant Request for Proposals: Improving Venous Thromboembolism (VTE) Diagnosis and Treatment within Primary Care Settings
Pfizer Inc.'s grant supports projects that improve VTE diagnosis, treatment, and management in primary care through evidence-based strategies and clinician education.
Funder: Pfizer Inc.
Due Dates: September 30, 2026 (Submission deadline, full proposal — 11:59 p.m. Eastern Time)
Funding Amounts: Up to $250,000 per project; project duration up to 24 months; total available budget is $250,000.
Summary: Funds quality improvement projects to enhance VTE diagnosis, treatment, and management in primary care through evidence-based strategies and clinician education.
Key Information: Only organizations (not individuals) may apply; U.S.-based projects only; IRB approval may be required before funding is released.
Description
This grant opportunity, supported by Pfizer Inc. in partnership with the American Academy of Family Physicians (AAFP) and the Pfizer/Bristol-Myers Squibb Alliance, seeks proposals for quality improvement (QI) projects aimed at improving the recognition, diagnosis, treatment, and management of venous thromboembolism (VTE) in family medicine and primary care settings in the United States. The focus is on empowering clinicians to implement evidence-based tools and strategies, enhance patient adherence, and translate educational interventions into measurable clinical improvements. Projects should address gaps in clinician knowledge and performance, support the consistent use of risk assessment tools, and foster multidisciplinary collaboration to optimize patient outcomes and reduce VTE-related harm and hospitalizations.
